Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients

Abstract

SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.